Business Context and Reporting Period
Company: Synthetic Blood International, Inc. (Note: Metadata referenced "Tenax Therapeutics," but the filing text identifies the registrant as Synthetic Blood International, Inc.)
Reporting Period: Quarterly period ended July 31, 2005.
Business Stage: Development stage company focused on perfluorocarbon-based medical products, primarily "Oxycyte" (a synthetic blood substitute) and a glucose biosensor implant. The company is currently conducting Phase II clinical trials for Oxycyte.
Key Financial Metrics
| Metric | Three Months Ended July 31, 2005 | Three Months Ended July 31, 2004 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(612,348) | $(473,422) |
| Loss Per Share (Basic & Diluted) | $(0.005) | $(0.004) |
| Cash and Cash Equivalents (End of Period) | $1,281,423 | $536,621 |
| Working Capital | $1,238,484 | Filing text does not provide a clear value for prior period |
| Accumulated Deficit (Inception to Date) | $(24,235,079) | N/A |
| Convertible Debentures (Principal) | ~$1.85 million (Issued July 2005) | N/A |
Cash Flow Summary (Three Months Ended July 31, 2005):
- Net cash used in operating activities: $(742,668)
- Net cash used in investing activities: $(16,902)
- Net cash provided by financing activities: $1,452,230
Material Changes vs. Prior Period
- Expenses: Total expenses increased by $140,760 compared to the prior year quarter. Research and Development (R&D) expenses rose to $340,173 from $219,466, driven by the initiation of Phase II clinical trials ($110,856 in the quarter). General and Administrative expenses increased to $275,667 from $255,614, largely due to a $34,000 increase in investor relations costs.
- Liquidity: Cash and cash equivalents increased significantly from $536,621 to $1,281,423, primarily due to financing activities.
- Financing: The company closed a significant financing transaction in July 2005, issuing unsecured convertible debentures with a principal amount of approximately $1.85 million. Net proceeds were approximately $1.13 million to $1.145 million after discounts and fees.
Outlook, Risks, and Management Commentary
- Clinical Progress: The company is actively enrolling patients in a Phase II orthopedic surgery trial for Oxycyte (targeting 60 patients). Two additional Phase II proof-of-concept studies (brain ischemia and sickle cell crisis) are expected to start in September or October 2005.
- Capital Needs: Management estimates the cost of pursuing Phase II clinical trials in 2005 and 2006 at $8,000,000. Current cash and recent financing are expected to fund operations for at least the next 6 months. Future funding beyond calendar year 2005 is not assured.
- Going Concern: The filing explicitly states that the company's continuation as a going concern is dependent on its ability to obtain additional financing. Substantial doubt exists regarding the company's ability to continue as a going concern without further capital.
- Accounting Changes: The company is assessing the impact of SFAS No. 123(R), which requires the expensing of share-based compensation using the fair value method, effective May 1, 2006. This is expected to increase non-cash charges.
Investor Verification Checklist
- Capital Runway: Verify if the company has secured additional funding beyond the 6-month runway mentioned by management to cover the estimated $8 million Phase II trial costs.
- Convertible Debt Terms: Review the specific conversion rates and warrant terms of the $1.85 million debentures issued in July 2005 to assess potential dilution.
- Clinical Trial Enrollment: Confirm the status of patient enrollment for the Phase II orthopedic trial and the start dates for the brain ischemia and sickle cell crisis studies.
- Related Party Transactions: Note the $32,100 paid to a specialty contract manufacturer where an officer is a minority shareholder and director.
- Stock-Based Compensation Impact: Monitor the adoption of SFAS 123(R) and its effect on future reported net losses.